Use of Tenofovir for PrEP in Women in Africa
A randomized, controlled trial that was part of the VOICE study compared oral tenofovir, tenofovir-emtricitabine combo, and tenofovir vaginal gel in efficacy for preexposure prophylaxis in African women. During the trial, adherence to medication regimen was low and overall, none of the versions of tenofovir were found to be an effective method of PrEP against HIV.
Citation:
Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, Taljaard M, Parikh UM, Piper J, Masse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM,; VOICE Study Team. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015 Feb 5;372(6):509-18.
Original Article (subscription may be required)
Editorial:
Saag MS. Preventing HIV in women - Still trying to find their VOICE. N Eng J Med. 2015 Feb 5;372(6):564-6.
Original Article (subscription may be required)
